Background/Aim: Stimulant medications can enhance mood and cognition in stroke rehabilitation, but human clinical trial results are inconclusive. We sought to prospectively study the effects of levodopa (LD) and/or methylphenidate (MPH) in combination with physiotherapy on mood and cognition following stroke in human subjects. Methods: Ischemic stroke patients were enrolled in our study 15 to 180 days after stroke onset. The patients were randomized into four medication groups (MPH, LD, MPH + LD, or placebo) and received a 15-day course of medication therapy (1 dose daily) and 45-min standard physiotherapy treatment daily. Mood and cognitive function were assessed at the study onset and 15, 90 and 180 days after study enrollment. Results: The strongest improvement of mood and cognition was found between baseline and the first follow-up immediately after the intervention. A significant improvement in mood was also found in the combined treatment group (MPH + LD) at 90 and 180 days, compared to the placebo group. Conclusions: A 15-day course of daily MPH + LD combined with physiotherapy over a 3-week period was safe and significantly improved mood status in ischemic stroke patients. Future studies are needed which determine the optimal therapeutic window for and dosage of psychostimulants as well as identify those stroke patients who might benefit the most from treatment.

1.
Poynter B, Shuman M, Diaz-Granados N, Kapral M, Grace SL, Stewart DE: Sex differences in the prevalence of post-stroke depression: a systematic review. Psychosomatics 2009;50:563–569.
2.
Provinciali L, Coccia M: Post-stroke and vascular depression: a critical review. Neurol Sci 2002;22:417–428.
3.
Whyte EM, Mulsant BH: Post stroke depression: epidemiology, pathophysiology, and biological treatment. Biol Psychiatry 2002;52:253–264.
4.
Gaete JM, Bogousslavsky J: Post-stroke depression. Expert Rev Neurother 2008;8:75–92.
5.
Hackett ML, Anderson CS, House AO: Management of depression after stroke: a systematic review of pharmacological therapies. Stroke 2005;36:1092–1103.
6.
Barry S, Dinan TG: Alpha-2 adrenergic receptor function in post-stroke depression. Psychol Med 2009;20:305–309.
7.
Orr K, Taylor D: Psychostimulants in the treatment of depression: a review of the evidence. CNS Drugs 2007;21:239–257.
8.
Leonard BE, McCartan D, White J, King DJ: Methylphenidate: a review of its neuropharmacological, neuropsychological and adverse clinical effects. Hum Psychopharmacol 2004;19:151–180.
9.
Kline AE, Chen MJ, Tso-Olivas DY, Feeney DM: Methylphenidate treatment following ablation-induced hemiplegia in rat: experience during drug action alters effects on recovery of function. Pharmacol Biochem Behav 1994;48:773–779.
10.
Nutt JG, Fellman JH: Pharmacokinetics of levodopa. Clin Neuropharmacol 1984;7:35–50.
11.
Grade C, Redford B, Chrostowski J, Toussaint L, Blackwell B: Methylphenidate in early poststroke recovery: a double-blind, placebo-controlled study. Arch Phys Med Rehabil 1998;79:1047–1050.
12.
De Wit L, Kamsteegt H, Yadav B, Verheyden G, Feys H, De Weerdt W: Defining the content of individual physiotherapy and occupational therapy sessions for stroke patients in an inpatient rehabilitation setting. Development, validation and inter-rater reliability of a scoring list. Clin Rehabil 2007;21:450–459.
13.
Gladstone DJ, Danells CJ, Armesto A, McIlroy WE, Staines WR, Graham SJ, Herrmann N, Szalai JP, Black SE, Subacute Therapy with Amphetamine and Rehabilitation for Stroke Study Investigators: Physiotherapy coupled with dextroamphetamine for rehabilitation after hemiparetic stroke: a randomized, double-blind, placebo-controlled trial. Stroke 2006;37:179–185.
14.
Masand P, Pickett P, Murray GB: Psychostimulants for secondary depression in medical illness. Psychosomatics 1991;32:203–208.
15.
Kempster PA, Frankel JP, Bovingdon M, Webster R, Lees AJ, Stern GM: Levodopa peripheral pharmacokinetics and duration of motor response in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1989;52:718–723.
16.
Lazarus LW, Winemiller DR, Lingam VR, Neyman I, Hartman C, Abassian M, Kartan U, Groves L, Fawcett: Efficacy and side effects of methylphenidate for poststroke depression. J Clin Psychiatry 1992;53:447–449.
17.
Johnson G, Burvill PW, Anderson CS, Jamrozik K, Stewart-Wynne EG, Chakera TM: Screening instruments for depression and anxiety following stroke: experience in the Perth community stroke study. Acta Psychiatr Scand 1995;91:252–257.
18.
Agrell B, Dehlin O: Comparison of six depression rating scales in geriatric stroke patients. Stroke 1989;20:1190–1194.
19.
Malakouti SK, Fatollahi P, Mirabzadeh A, Salavati M, Zandi T: Reliability, validity and factor structure of the GDS-15 in Iranian elderly. Int J Geriatr Psychiatry 2006;21:588–593.
20.
Folstein MF, Folstein SE, McHugh PR: Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–198.
21.
Foroughan M, Jafari Z, Shirinbayan P, Ghaemmagham Farahani Z, Rahgozar M: Validation of mini-mental state examination (MMSE) in the elderly people in Tehran. Advances in Cognitive Science 2008;38:29–33.
22.
Lazarus LW, Moberg PJ, Langsley PR, Lingam VR: Methylphenidate and nortriptyline in the treatment of poststroke depression: a retrospective comparison. Arch Phys Med Rehabil 1994;75:403–406.
23.
Popkin MK, Callies AL, Mackenzie TB: The outcome of antidepressant use in the medically ill. Arch Gen Psychiatry 1985;42:1160–1163.
24.
Macleod AD: Methylphenidate in terminal depression. J Pain Symptom Manage 1998;16:193–198.
25.
Ng KC, Chan KL, Straughan PT: A study of post-stroke depression in a rehabilitative center. Acta Psychiatr Scand 2007;92:75–79.
26.
Williams LS, Ghose SS, Swindle RW: Depression and other mental health diagnoses increase mortality risk after ischemic stroke. Am J Psychiatry 2004;161:1090–1095.
27.
Carod-Artal J, Egido JA, González JL, Varela de Seijas E: Quality of life among stroke survivors evaluated 1 year after stroke: experience of a stroke unit. Stroke 2000;31:2995–3000.
28.
Kimura M, Robinson RG, Kosier JT: Treatment of cognitive impairment after poststroke depression: a double-blind treatment trial. Stroke 2000;31:1482–1486.
29.
Lokk J, Roghani RS, Delbari A: Effect of methylphenidate and/or levodopa coupled with physiotherapy on functional and motor recovery after stroke – a randomized, double blind, placebo controlled trial. Acta Neurol Scand 2011;123:266–273.
30.
Chemerinski E, Robinson RG, Kosier JT: Improved recovery in activities of daily living associated with remission of poststroke depression. Stroke 2001;32:113–117.
31.
Masand P, Murray GB, Pickett P: Psychostimulants in post-stroke depression. J Neuropsychiatry Clin Neurosci 1991;3:23–27.
32.
Massie MJ, Holland J:C Depression and the cancer patient. J Clin Psychiatry 1990;51(7 suppl):12–19.
33.
Woods SW, Tesar GE, Murray GB, Cassem NH: Psychostimulant treatment of depressive disorders secondary to medical illness. J Clin Psychiatry 1986;47:12–15.
34.
Johnson ML, Roberts MD, Ross AR, Witten CM: Methylphenidate in stroke patients with depression. Am J Phys Med Rehabil 1992; 71:239–241.
35.
Goodman L, Gilman A: Goodman and Gilman’s The Pharmacological Basis of Therapeutics. New York, MacMillan Publishing Company, 1985.
36.
Challman TD, Lipsky JJ: Methylphenidate: its pharmacology and uses. Mayo Clin Proc 2000;75:711–721.
37.
Robinson RG: The Clinical Neuropsychiatry of Stroke: Cognitive, Behavioral, and Emotional Disorders following Vascular Brain Injury. Cambridge, Cambridge University Press, 1998.
38.
Zhou DH, Wang JY, Li J, Deng J, Gao C, Chen M: Frequency and risk factors of vascular cognitive impairment three months after ischemic stroke in China: the Chongqing stroke study. Neuroepidemiology 2005;24:87–95.
39.
Grondin R, Zhang Z, Gerhardt GA, Gash DM: Dopaminergic therapy improves upper limb motor performance in aged rhesus monkeys. Ann Neurol 2000;48:250–253.
40.
Cramer SC: Repairing the human brain after stroke. I. Mechanisms of spontaneous recovery. Ann Neurol 2008;63:272–287.
41.
Seniów J, Litwin M, Litwin T, Lesniak M, Czlonkowska A: New approach to the rehabilitation of post-stroke focal cognitive syndrome: effect of levodopa combined with speech and language therapy on functional recovery from aphasia. J Neurol Sci 2009;283:214–218.
42.
Lee H, Kim SW, Kim JM, Shin IS, Yang SJ, Yoon JS: Comparing effects of methylphenidate, sertraline and placebo on neuropsychiatric sequelae in patients with traumatic brain injury. Hum Psychopharmacol 2005;20:97–104.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.